Clincosm LogoSign in Get a demo

Rehabilitation Needs of the Malaysian Haematological Cancer Survivors

Sponsor
University of Malaya (Other)
Overall Status
Completed
CT.gov ID
NCT04236063
Collaborator
(none)
168
Enrollment
1
Location
10.5
Actual Duration (Months)
15.9
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

Many cancers are being treated more effectively nowadays due to the raised awareness and early detection as well as advancement in researches and technology. Despite the rising number of cancer survivors in the coming years, these survivors are still plagued by the poor quality of life due to physical and psychological impairment. According to the National Cancer Registry Report from 2007-2011, haematological cancer is one of the ten most common cancers in Malaysian population. Many haematological cancer survivors in Malaysia are reportedly having poor quality of life due to multiple physical and emotional impairments which leads to further disability in life. It is thus an important effort to identify the rehabilitation needs in these cancer survivors to implement alternatives to improve the disease outcome through cancer rehabilitation.

Condition or Disease Intervention/Treatment Phase
  • Other: WHODAS 2.0 Questionnaire

Detailed Description

A cross-sectional questionnaire-based study will be employed to identify the rehabilitation needs and predictors of needs in outpatient hemato-oncological cohort at UMMC Hemato-oncology Clinic for 12 months. The validated questionnaire employed evaluates the potential disabilities that could affect the aforementioned patients in domains such as communication, independence in mobility, self-care, social participation, handling relationships and domestic activity of daily living a month prior to the survey.

Participants of age between 18 to 80 years old, diagnosed with haemato-oncological illnesses will be screened; excluding potential participants who are too ill or cannot understand English, Malay, or Chinese; to be recruited in the research.

Based on the findings from the analysis, rehabilitation needs could be tailored accordingly to improve quality of life of these patients

Study Design

Study Type:
Observational [Patient Registry]
Actual Enrollment :
168 participants
Observational Model:
Other
Time Perspective:
Cross-Sectional
Official Title:
Rehabilitation Needs of the Malaysian Haematological Cancer Survivors Through a Single Centre Experience
Actual Study Start Date :
Jul 15, 2019
Actual Primary Completion Date :
Mar 31, 2020
Actual Study Completion Date :
May 31, 2020

Arms and Interventions

Arm Intervention/Treatment
Haematological malignancy

Patients with haematological malignancy

Other: WHODAS 2.0 Questionnaire
36-item WHODAS 2.0 questionnaire will be used for each patient to identify difficulty faced by patient over past 30 days from the day of interview

Outcome Measures

Primary Outcome Measures

  1. World Health Organization Disability Assessment Schedule (WHODAS) 2.0 [30 days ago from interview date]

    WHODAS 2.0 is a practical, generic assessment tool that measures health and disability at population level or in clinical practice. It identifies possible disabilities in 6 domains of life namely Cognitive, Mobility, Self Care, Relationship, Life Activities and Participation. In view of its resemblance to the International Classification of Functioning, Disability and Health (ICF) model, direct identification of functioning and disability separately from the disease condition could be done. Each domain has few sets of questions pertaining to the activities; the responses and scores of each question are divided into none (0), mild (1), moderate (2), severe (3) and extremely cannot do (4). The scores from each domain will be summed and higher scores signifies higher disability status.

Secondary Outcome Measures

  1. Identifying patients who are at risk of disability from haemato-oncological illness [30 days ago from interview date]

    Disability outcomes of different groups of patients (of demographics and diagnosis) were analyzed using SPSS program and identification of patients who were vulnerable to haematological cancers were done using ANOVA test.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 80 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:

  • patient with haematological malignancy

  • agreeable to participate in the interview

Exclusion Criteria:

  • ill at the time of follow up

  • unable to understand English, Malay or Chinese

  • refuse to be interviewed

Contacts and Locations

Locations

Site City State Country Postal Code
1 University Malaya Kuala Lumpur Wilayah Persekutuan Malaysia 59100

Sponsors and Collaborators

  • University of Malaya

Investigators

  • Principal Investigator: SOO CHIN CHAN, MASTERS, SENIOR LECTURER AND REHABILITATION PHYSICIAN
  • Principal Investigator: ANWAR SUHAIMI, MASTERS, SENIOR LECTURER AND REHABILITATION PHYSICIAN

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Chan Soo Chin, Senior Lecturer and Rehabilitation Physicians, University of Malaya
ClinicalTrials.gov Identifier:
NCT04236063
Other Study ID Numbers:
  • 201945-7310
First Posted:
Jan 22, 2020
Last Update Posted:
Nov 4, 2020
Last Verified:
Nov 1, 2020
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Chan Soo Chin, Senior Lecturer and Rehabilitation Physicians, University of Malaya
Cross sectional study
Additional relevant MeSH terms:
Hematologic Neoplasms
Multiple Myeloma
Neoplasms, Plasma Cell

Study Results

No Results Posted as of Nov 4, 2020